logo
8-year-old whose rare condition put him in a wheelchair can walk again — thanks to an experimental drug made just for him

8-year-old whose rare condition put him in a wheelchair can walk again — thanks to an experimental drug made just for him

New York Post10-07-2025
An eight-year-old boy has regained his ability to walk with the aid of a compound found in a common over-the-counter supplement.
The boy's case was detailed in the journal Nature.
The unnamed child was an active athlete until the summer of 2023, when he began to struggle with mobility. Within months, his symptoms progressed to the point that he required a wheelchair.
'Our son's condition dramatically changed in a short period. He went from being the fastest runner in his class and an avid soccer player to struggling just to walk, often limping and experiencing frequent falls,' the boy's parents, who wish to remain anonymous, said to STAT News.
3 Their son was eventually diagnosed with HPDL deficiency, a rare genetic condition that inhibits the body's ability to produce sufficient levels of coenzyme Q10 (CoQ10), a compound critical to cell function.
Prostock-studio – stock.adobe.com
Their son was eventually diagnosed with HPDL deficiency, a rare genetic condition that inhibits the body's ability to produce sufficient levels of coenzyme Q10 (CoQ10), a compound critical to cell function.
HPDL deficiency occurs when an individual inherits two mutated versions of the human HPDL gene, which is used in the production of the CoQ10 enzyme.
Without adequate CoQ10, patients struggle with muscle control, walking, and are at a higher risk of seizures.
When HPDL deficiency surfaces later in adolescence, it manifests as muscle weakness and stiffness in otherwise healthy children.
The boy in question was placed on a protocol of CoQ10 supplements — but the pills could only help to a certain extent, as the enzyme is too large to cross the blood-brain barrier.
'[CoQ10] is safe. It's reasonably effective at treating symptoms outside of the brain, but almost completely ineffective at treating symptoms within the brain, because it doesn't get through the blood-brain barrier,' Michael Pacold, an associate professor of radiation oncology at NYU Langone and one of the study authors, told STAT.
But 4-HB is a building block of CoQ10 — and, helpfully, it's thin enough to cross the blood-brain barrier and can be condensed into a powder that is dissolved in a water solution.
3 CoQ10 is available as an over-the-counter supplement to help boost energy and combat fatigue.
luchschenF – stock.adobe.com
The FDA has not approved CoQ10 or 4-HB as a treatment for any specific disease or condition. However, CoQ10 is available as an over-the-counter supplement to help boost energy and combat fatigue.
While 4-HB is not approved by the FDA, with the consent of the boy's parents and the insistence of his doctors, the FDA approved its use as a single-patient investigational drug — in other words, doctors were permitted to use an unapproved drug for a specific patient to treat a specific condition.
'It was one of the hardest decisions we've ever made [to try the experimental treatment], but doing nothing felt riskier,' said the boy's parents.
'We saw how quickly our son was declining and knew we had to act. After speaking with doctors and doing our research, we got hope and confidence to step into the unknown.'
3 Within a month of receiving treatment, the boy was walking again and even completed a nearly mile-long trek across Central Park.
maxximmm – stock.adobe.com
A 2021 study tested 4-HB on mice with HPDL deficiency and found that the supplement restored mobility in rodents. Its use in the case of the eight-year-old body is the first time it's been used to treat the condition in humans.
After stopping his CoQ10 supplements, the boy began taking a 4-HB supplement in a 600ml solution. Equivalent to nearly three glasses of water, the liquid cure often caused him to vomit.
This was eventually reduced to a 300ml solution, or just over one glass of water.
However, the upchuck was worth the upturn, as within a month of receiving treatment, the boy was walking again, and even completed a nearly mile-long trek across Central Park.
Researchers are hopeful the success story will serve as a beacon to others. The research team is calling it a medical breakthrough.
'We all dream of this as scientists. And every morning I pinch myself … is this really a dream?' said Pacold.
Now, Pacold and his team are working on a larger study to test the approach on a larger group of children.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

You're Ruining Your Gains If You Skip These 8 Recovery Foods
You're Ruining Your Gains If You Skip These 8 Recovery Foods

Yahoo

time2 hours ago

  • Yahoo

You're Ruining Your Gains If You Skip These 8 Recovery Foods

You're Ruining Your Gains If You Skip These 8 Recovery Foods originally appeared on Men's Fitness. Men's Fitness aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. After an intense workout, the body needs to repair damaged muscle tissue. Pick the right food and you can jump-start that recovery process without ruining the gains you made in the gym. Amino acids—the building blocks of protein—are essential to bolstering recovery. And to ensure you get adequate amino acids, you need to eat protein. Your body also needs glycogen, found in carb-rich foods, since stores gets depleted during training. Eating a combo of protein and carbs is key to workout recovery, and foods that are good sources of both should become staples in your diet. Add these eight healthy eats to your diet to maximize recovery after a workout. Best Post-Workout Recovery Foods Lean Meat Although our bodies produce non-essential amino acids, we also need essential amino acids, ones that are not made in the body and must be consumed from our diets. One of the best sources of essential amino acids is lean meat such as chicken, turkey, and ground beef. According to the FDA, a 'lean' meat contains less than 10 grams of fat, 4.5 grams or less of saturated fat, and less than 95 milligrams of cholesterol per 100 grams. Choose meats that are at least 90 percent lean to ensure you're not getting too much saturated fat and cholesterol. Quinoa One cup of cooked quinoa contains about 8 grams of protein and 40 grams of carbohydrates, making it a nutrient-packed post-workout dish. Unlike other grains, quinoa is a complete protein since it contains all nine essential amino acids, which results in better muscle recovery and more energy. Plain Greek Yogurt Greek yogurt has 15 to 20 grams of protein per 6 ounces compared to 9 grams of protein in an identical serving of regular yogurt. The protein in Greek yogurt is predominantly casein, which digests slower than whey and boasts a full essential amino acid profile. Opt for plain Greek yogurt since it has substantially less sugar than flavored Greek yogurt. To really capitalize on the benefits of casein, eat it before bedtime for extended amino acid digestion. Smoothies Smoothies make a great post-workout recovery drink because of the instant absorption of a custom assortment of nutrients. Just be mindful of how much sugar you add—piling on the fruit can quickly turn a post-workout "nutrition shake" into a secret sugar bomb. Bananas Nature designed the humble banana to be a post-workout recovery machine. One serving includes about 27 grams of carbohydrates, an essential energy resource to ignite your body's muscle repair systems. Additionally, a potassium-packed banana replenishes the depleted electrolyte stores in your muscles, reducing soreness and speeding up the recovery process. The best part is that bananas are naturally sweet, which means it's an ideal addition to a post-workout protein shake or smoothie without adding any refined sugar. Low-fat Chocolate Milk The perfect recovery ratio of carbohydrates to protein is 4:1, according to a growing collection of studies. Chocolate milk matches this ratio better than any sugary sports drink, turning the lunch box staple into a powerful recovery option. A study from Applied Physiology, Nutrition, and Metabolism also found exercisers are able to retain more than twice the amount of fluid in chocolate milk than in a sports drink after a workout, meaning the body is able to absorb more protein with less volume. Avocados Bananas get all the attention when it comes to potassium, but avocados actually have an average of 35 percent more per serving. The fruit is also full of monosaturated fats, which have been linked to reducing cholesterol levels. With an additional 3 grams of protein, vital for muscle growth, the avocado is a filling addition to a post-workout meal. Sweet Potatoes Another potassium powerhouse, the sweet potato contains 448 milligrams in one serving. Because of its orange hue it also comes packed with carotenoids—compounds that aid cell repair, which is vital during the recovery process after a workout. The starchy carbs from sweet potatoes also help restock energy stores, while the fiber will keep you full and encourage you not to spring for something less healthy later in the Ruining Your Gains If You Skip These 8 Recovery Foods first appeared on Men's Fitness on Aug 1, 2025 This story was originally reported by Men's Fitness on Aug 1, 2025, where it first appeared. Solve the daily Crossword

Alzheimer's researchers say targeting brain sugar could help protect against dementia
Alzheimer's researchers say targeting brain sugar could help protect against dementia

Yahoo

time4 hours ago

  • Yahoo

Alzheimer's researchers say targeting brain sugar could help protect against dementia

The brain has a hidden "sugar code" that could lead to better treatments for neurological diseases like Alzheimer's, according to new research. A study recently published in the journal Nature Metabolism found that breaking down glycogen (stored glucose) in the brain could reduce the buildup of toxic proteins linked to the common dementia. This was one of the first studies to show that glycogen may actively influence brain health and disease, according to lead author Dr. Pankaj Kapahi, a professor at the Buck Institute for Research on Aging in California. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects "The study began with fruit flies (Drosophila) that were genetically modified to mimic tauopathy, a condition where a protein called tau builds up in the brain, similar to what happens in Alzheimer's disease," Kapahi told Fox News Digital. The flies used in the study were found to have brain damage and shortened lifespans, according to the researcher. Read On The Fox News App To ensure that the results could translate to humans, the research team also studied nerve cells made in the lab from human patient cells carrying tau mutations, as well as postmortem brain samples from people who had Alzheimer's or related conditions, according to a press release. In both the fly and human models, the researchers found increased levels of glycogen (stored glucose) in the brain, as well as signs that glycogen breakdown was impaired, Kapahi told Fox News Digital. This was a surprising discovery, as researchers previously thought glycogen was mainly stored in the muscles and liver. Alzheimer's Risk Could Rise With Specific Sleep Pattern, Experts Warn They also found that the excess glycogen contributed to disease. The tau proteins in the scientists' models interacted with glycogen, blocking it from breaking down, and the nerves lost their ability to ward off cell damage. However, the researchers found they could decrease damage to the fruit flies and human nerves by boosting an enzyme called glycogen phosphorylase (GlyP), which breaks down glycogen. The nerve cells used the glycogen to fight against cell damage, suggesting that the enzymes responsible for breaking down sugar could be promising targets for future therapies. The researchers were also curious whether a restricted diet could improve the flies' brain health. When they reduced the amount of protein in the insects' diet, the flies indeed lived longer and their brain health improved. "We then discovered this improvement was linked to an increase in the breakdown of glycogen," Kapahi said. This led to the study's main finding — that breaking down glycogen in neurons can protect the brain from damage caused by tau buildup. Eating These Common Foods Could Reduce Alzheimer's Risk, Experts Say The scientists also developed a drug using a special molecule called 8-Br-cAMP that replicated similar effects of dietary restriction, the press release noted. The authors clarified that they are not recommending low-protein diets just yet — but said this research could pave the way for dietary or drug-based strategies to help slow Alzheimer's and related diseases. Dr. Michael Okun, a Florida neurologist and medical advisor to the Parkinson's Foundation, was not involved in the study but commented on the significance of the findings. "Instead of funneling sugar into energy-burning processes, the broken-down glycogen seemed to be routed into an antioxidant-producing pathway," Okun, who is also author of "The Parkinson's Plan," told Fox News Digital. "The next step in the process may be mopping up potentially damaging free radicals roaming our brains," he said. Okun also confirmed that dietary restrictions activated a protective brain pathway and boosted the breakdown of brain sugar. "It ultimately reduced damage from the Alzheimer's-related tau protein," he said. The study — which was supported by the National Institutes of Health, as well as the American Federation of Aging Research and other sources — did have some limitations, the experts acknowledged. Click Here To Sign Up For Our Health Newsletter The researchers did not clarify whether breaking down brain glycogen could stop human brain cells from dying, Okun noted. "We don't yet know why glycogen builds up in disease, or whether it's a cause or a result of tau pathology — though our data suggest it may amplify disease progression," Kapahi added. The research was also conducted only on fly and human cell models and has not yet been tested on living humans. "We still don't know if targeting glycogen breakdown will work in human patients — and most importantly, whether it will be a safe approach," Okun said. Alzheimer's disease, the most common form of dementia in the U.S., affects more than seven million people in the U.S., according to the Alzheimer's Association. For more Health articles, visit The neurological disorder affects memory, thinking and behavior. There is no cure for the disease, but some medications can temporarily slow progression and improve quality of article source: Alzheimer's researchers say targeting brain sugar could help protect against dementia Solve the daily Crossword

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

Yahoo

time5 hours ago

  • Yahoo

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule GLP-1 receptor agonist with bias for cAMP signaling pathway, discovered and developed by Innovent Biologics with proprietary rights. Preclinical data demonstrate its superior pharmacokinetic (PK) and physicochemical properties compared to peer compounds. In animal models, IBI3032 achieved 5 to 10 times higher oral exposure at equivalent doses, with improved efficacy and good tolerability in both GLP-1R KI DIO mice and obese monkey models, achieving comparable therapeutic effects at lower doses. The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025. Innovent is building up its CVM pipeline with mazdutide as the cornerstone, and the initiation of the IBI3032 clinical study marks a significant step in the evolution of its CVM pipeline portfolio with global potential. Dr. Lei Qian, Chief R&D Officer for General Biomedicines Pipeline at Innovent Biologics, said, "GLP-1 has emerged as a blockbuster target over the past decade. Its oral form, with its convenience, flexibility, and unique advantage in combination treatment strategies, holds promise as a differentiated complement to GLP-1R-targeting biologicals. Beyond traditional applications in diabetes and weight management, oral GLP-1 possess potential in treating related diseases such as hypertension and OSA (obstructive sleep apnea). IBI3032 has demonstrated its promising efficacy profiles in animal models, where IBI3032 exhibited a longer elimination half-life and higher drug exposure levels than its competitors at the same dose. We are excited to advance this candidate into clinical development. This IND approval reflects Innovent's strong R&D capabilities and, most importantly, our commitment to global innovation. We hope that in the near future, IBI3032 can offer more effective and convenient treatment options to benefit patients around the world. " About IBI3032 IBI3032 is a novel oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA). By efficiently and selectively targeting GLP-1R, it activates downstream signal transduction, thereby delaying gastric emptying, inhibiting appetite, and promoting insulin secretion, and ultimately supporting the treatment of insulin-related metabolic diseases such as obesity and T2DB. Discovered through a structure-based drug design (SBDD) strategy combined with systematic physicochemical property optimization, IBI3032 has shown better PK and physicochemical properties compared to similar compounds. The IND application of IBI3032 was accepted by China's National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical study of IBI3032 is planned for initiation in the second half of 2025. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2)Ramucirumab (Cyramza),Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store